UroGen Pharma (URGN) reported Q1 EPS of ($1.07), $0.26 better than the analyst estimate of ($1.33).
As of March 31, 2022, cash and cash equivalents were $138.1 million plus an additional $150 million in liquidity for which Phathom is eligible to receive, which includes $100 million in proceeds from the revenue interest financing agreement announced on May 4, 2022 and $50 million from its term loan with Hercules Capital (NYSE:HTGC).